The role of therapeutic drug monitoring in treatment of HIV infection

British Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2001, Pages 301-308

  Back, David J ^a   Khoo, Saye H ^a   Gibbons, Sara E ^a   Merry, Concepta ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Inhibitory quotient; Pharmacoenhancement; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT PLANNING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035029205     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.01380.x     Document Type: Article

References (45)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Analysis of HIV-1 clinical trials: Statistical magic?
3. Clinical progression and virological failure on highly active anti-retroviral therapy in HIV-1 patients: A prospective cohort study
4. Virological response to protease inhibitor therapy in an HIV clinic cohort
5. Outcome and predictors of failure of highly active anti-retroviral therapy: One-year follow-up of a cohort of human immunodeficiency type-1-infected persons
6. Pharmacokinetics and potential interactions amongst anti-retroviral agents used to treat patients with HIV infection
7. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
8. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
9. The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
10. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
11. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
12. Relationship between indinavir pharmacokinetics and antiviral activity in phase I/II trials
13. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
14. Ritonavir
15. Resistance to anti-human immunodeficiency virus therapeutic agents
16. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
17. Mechanisms of virological failure in previously untreated HIV infected patients from a trial of induction-maintenance therapies
18. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir containing regimens
19. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
20. Indinavir pharmacokinetics and relationships between exposure and antiviral effect
21. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
22. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy
23. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotypic-guided therapy: Pharmacological data from the VIRADAPT study
24. Variability in trough plasma saquinavir concentrations in HIV patients - A case for therapeutic drug monitoring
25. Human serum attenuates the activity of protease inhibitors towards wild type and mutant human immunodeficiency virus
26. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
27. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter
28. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
29. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
30. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
31. Cellular influx/efflux of protease inhibitors in vitro
32. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
33. Improved tolerability of ritonavir derived from pharmacokinetic principles
34. Rate of onset of hyperlipidaemia following treatment with ritonavir/saquinavir and correlation with drug levels
35. Therapeutic drug monitoring of nelfinavir in HIV patients with liver disease
36. Serious adverse effects (SAE) in a prospective cohort of HIV-infected adults started on protease inhibitor therapy (ANRS EP11 Study)
37. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps
38. Monitoring of plasma drug levels to assess non-adherence to drug therapy
39. ATHENA, a randomised controlled clinical trial to evaluate whether therapeutic drug monitoring (TDM) contributed to reduced HIV-related morbidity and mortality
40. Pharmacology Committee position paper on therapeutic drug monitoring for anti-retroviral drugs. Using drug concentrations to guide individual therapy
41. The steady-state plasma concentrations of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals
42. Modulation of Saquinavir Steady State: Pharmacokinetics with 'baby' doses of ritonavir in healthy volunteers
43. Ritonavir intensification in indinavir recipients with detectable HIV RNA levels